Stay updated on Pfizer Press Releases

Sign up to get notified when there's something new on the Pfizer Press Releases page.
Latest website image capture
Clouds background image

Latest updates to the Pfizer Press Releases page

  1. Check
    6 days ago
    Change Detected
    Summary
    Update shifts focus from a mid-2025 trial result announcement to dividend news for Q4 2025 and October 2025 timelines; removes the June 2025 trial result mention.
    Difference
    9%
    Check dated 2025-10-13T09:20:37.000Z thumbnail image
  2. Check
    13 days ago
    Change Detected
    Summary
    Core page content updated with a major pricing/partnership announcement; older dividend notice removed. No conflicting items; the new addition replaces the less important deleted item.
    Difference
    7%
    Check dated 2025-10-06T05:40:42.000Z thumbnail image
  3. Check
    21 days ago
    Change Detected
    Summary
    Adds multiple new 2025 corporate, clinical, and regulatory updates (trial results, licensing, approvals, earnings) and removes several older, related news items to reduce duplication; overall, a shift toward more current and forward-looking content.
    Difference
    30%
    Check dated 2025-09-29T03:09:03.000Z thumbnail image
  4. Check
    28 days ago
    No Change Detected
  5. Check
    35 days ago
    Change Detected
    Summary
    Shifts focus from oncology news to vaccine updates and accessibility: adds Pfizer/BioNTech vaccine content with dates and an Accessibility Statement, and removes the BRAFTOVI cancer news item.
    Difference
    13%
    Check dated 2025-09-14T19:27:17.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    The page now includes the FDA approval of Pfizer and BioNTech’s COMIRNATY® vaccine for specific age groups, while the previous mention of Astellas and Pfizer’s XTANDI™ research has been removed.
    Difference
    13%
    Check dated 2025-08-31T12:06:33.000Z thumbnail image
  7. Check
    63 days ago
    Change Detected
    Summary
    The page now includes information about the significant survival benefits of PADCEV™ Plus KEYTRUDA™ for bladder cancer patients, while a previous announcement regarding Pfizer's licensing agreement has been removed.
    Difference
    10%
    Check dated 2025-08-17T04:35:53.000Z thumbnail image

Stay in the know with updates to Pfizer Press Releases

Enter your email address, and we'll notify you when there's something new on the Pfizer Press Releases page.